Compare Vaxcyte Inc. Common Stock (PCVX) vs First Trust Cloud Computing ETF (SKYY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Vaxcyte Inc. Common Stock vs First Trust Cloud Computing ETF — how do they compare? Vaxcyte Inc. Common Stock trades at $67.37 (market cap $10.51B), while First Trust Cloud Computing ETF trades at $163.94 (market cap $3.57B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 2.9× First Trust Cloud Computing ETF's market cap, and First Trust Cloud Computing ETF is more actively traded (236,993 versus 2,644,694). Which is the better fit depends on your goals — on Pluang, investors hold Vaxcyte Inc. Common Stock for 0 Days and First Trust Cloud Computing ETF for 84 Days on average.
| PCVX | SKYY | |
|---|---|---|
Market Cap | $10.51B | $3.57B |
Volume | 2,644,694 | 236,993 |
Sector | Health | — |
52-Week High | $73.82 | $174.89 |
52-Week Low | $40.32 | $104.16 |
Typical Hold Time | 0 Days | 84 Days |
Enterprise Value | $9.14B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SKYY, the First Trust Cloud Computing ETF, trades at $171.52, down 0.57% today but near its 52-week high. Technical indicators show a bullish trend with strong moving average support, though RSI suggests mild overbought conditions. The ETF provides diversified exposure to the cloud computing sector, benefiting from AI adoption and digital transformation trends. Recent news highlights institutional adjustments and positive coverage on cloud infrastructure growth.
The outlook for SKYY is positive, driven by secular trends in cloud computing and AI. Investment opportunities include sector growth and diversification benefits, while risks involve market volatility and sector-specific competition. The ETF's performance hinges on continued tech infrastructure spending and macroeconomic conditions affecting tech stocks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Vaxcyte Inc. Common Stock
Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →About First Trust Cloud Computing ETF
The fund will normally invest at least 90% of its net assets (including investment borrowings) in the common stocks and depositary receipts that comprise the index. The index is designed to track the performance of companies involved in the cloud computing industry.
Read more on SKYY →
